Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription 05.01.2026 1 AJR Am J Roentgenol 1 Anticancer Res 2 BMC Cancer 2 BMC Urol 1 Br J Cancer 1 Br J Radiol 2 Cancer 1 Eur J Radiol 1 Eur Radiol 2 Eur Urol 3 Int J Urol 1 Invest Radiol 1 J Natl Cancer Inst 1 J Nucl Med 1 J Urol 1 Lancet Oncol 1 PLoS Genet 2 PLoS One 2 Proc Natl Acad Sci U S A 1 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. COSTA DN
   Toward Consistent and Actionable MRI Reporting for Prostate Cancer Staging.
   AJR Am J Roentgenol. 2025 Dec 24. doi: 10.2214/AJR.25.34410.
   PubMed        
   
   

   
   Anticancer Res

2. RADES D, Janssen S, Thieme C, Kristiansen C, et al
   Impact of the Pre-radiotherapy Volume of the Urinary Bladder on its Filling Status During Hypo-fractionated Treatment for Prostate Cancer.
   Anticancer Res. 2026;46:283-292.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. ZHAI CF, Yang X, Qi X, Yang HK, et al
   Quantification of intratumoral heterogeneity using habitat-based MRI radiomics for predicting high-Gleason scores and castration-resistant PCa: retrospective study.
   BMC Cancer. 2025;25:1927.
   PubMed         Abstract available
   
   
4. MALEKI M, Mardani A, Sadeghi N, Allahmoradi Z, et al
   The impact of digital interactive interventions on survivorship outcomes in prostate cancer: a systematic narrative review.
   BMC Cancer. 2025 Dec 22. doi: 10.1186/s12885-025-15486.
   PubMed         Abstract available
   
   

   
   BMC Urol

5. SHIN JW, Sull JW, Minh NT, Jee SH, et al
   Prostate cancer risk and antioxidant biomarkers: the age-dependent reversal of bilirubin's role.
   BMC Urol. 2025 Dec 24. doi: 10.1186/s12894-025-02029.
   PubMed         Abstract available
   
   
6. BAZARBASHI S, Abdelmotal AS, Arabi T, Fallatah W, et al
   Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia.
   BMC Urol. 2025;25:306.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. NAIR-SHALLIKER V, Smith DP, Gebski V, Patel MI, et al
   High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).
   Br J Cancer. 2025 Dec 21. doi: 10.1038/s41416-025-03278.
   PubMed         Abstract available
   
   

   
   Br J Radiol

8. TRAN MN, Didiodato G, Lamb A, Quinn P, et al
   A Retrospective Comparative Evaluation of Rectal Preparation Strategies for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
   Br J Radiol. 2025 Dec 22:tqaf314. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Cancer

9. DUDIPALA H, Nazari SS, Werneck da Cunha I, Coligado N, et al
   Molecular alteration profiles characterize intraductal carcinoma of the prostate.
   Cancer. 2026;132:e70238.
   PubMed         Abstract available
   
   
10. GEBRAEL G, Agarwal N, Morgans AK, Vince R Jr, et al
    Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.
    Cancer. 2026;132:e70236.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

11. XIANG F, Zeng Y, Zhang Z, Zhang Y, et al
    Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer.
    Eur J Radiol. 2025;195:112614.
    PubMed         Abstract available
    
    

    
    Eur Radiol

12. BRATT O
    Efficacy endpoints of MRI-based prostate cancer screening: an epidemiological perspective.
    Eur Radiol. 2025 Dec 23. doi: 10.1007/s00330-025-12244.
    PubMed        
    
    

    
    Eur Urol

13. BARATA PC, Grier AL
    Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [(177)Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2025 Dec 19:S0302-2838(25)04858-4. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
14. FALKENBACH F, Beyer B, Graefen M
    Reply to Salvatore Cozzi and Thomas Zilli's, and Alexander Ho and Sean Sachdev's Letters to the Editor re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men Wi
    Eur Urol. 2025 Dec 27:S0302-2838(25)04868-7. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Int J Urol

15. KOKETSU Y, Iwamoto H, Hiratsuka K, Inaba T, et al
    Whole-Blood RNA Expression of Immunosuppressive Cell-Related Genes Is Associated With Prostate Cancer Progression.
    Int J Urol. 2025 Dec 21. doi: 10.1111/iju.70323.
    PubMed         Abstract available
    
    
16. HAGIMOTO H, Sakamoto S, Sato K, Nakamura K, et al
    Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70326.
    PubMed         Abstract available
    
    
17. FUKIAGE Y, Taga M, Inamura M, Kaeriyama K, et al
    Magnetic Resonance Imaging-Transrectal Ultrasound Fusion-Targeted Biopsy Improves the Diagnostic Efficacy of Overall and Clinically Significant Prostate Cancer.
    Int J Urol. 2025 Dec 26. doi: 10.1111/iju.70334.
    PubMed         Abstract available
    
    

    
    Invest Radiol

18. UMAPATHY L, Johnson PM, Dutt T, Tong A, et al
    Leveraging Representation Learning for Bi-parametric Prostate MRI to Disambiguate PI-RADS 3 and Improve Biopsy Decision Strategies.
    Invest Radiol. 2026;61:127-135.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

19. SPAUR M, Koutros S, Hurwitz LM, Manley CK, et al
    Drinking water nitrate, disinfection byproducts, and prostate cancer incidence in the Agricultural Health Study.
    J Natl Cancer Inst. 2025 Dec 5:djaf350. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

20. HOEKSTRA RJ, Peeters L, Beulens A, Roef MJ, et al
    Prospective Histopathologic Comparison Between [(18)F]PSMA-1007 PET/CT and [(18)F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270650. doi: 10.2967/jnumed.125.270650.
    PubMed         Abstract available
    
    

    
    J Urol

21. LUCIA MS, Callis S, Tangen C, Almutairi F, et al
    Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using ISUP Criteria: Inter- and Intra-Observer Concordance and Implications for Active Surveillance.
    J Urol. 2025 Dec 29:101097JU0000000000004919. doi: 10.1097/JU.0000000000004919.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

22. FIZAZI K, Saad F, Alonso-Gordoa T, Zurawski B, et al
    Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2026;27:68-78.
    PubMed         Abstract available
    
    

    
    PLoS Genet

23. WANG C, Tang T, Wang Y, Li J, et al
    Decoding the germline genetic architecture of prostate cancer at a single cell resolution.
    PLoS Genet. 2025;21:e1011975.
    PubMed         Abstract available
    
    

    
    PLoS One

24. CAO H, Pan A, Chen Y, Zheng F, et al
    TDP2 drives immune evasion and metastatic progression in prostate cancer.
    PLoS One. 2026;21:e0339607.
    PubMed         Abstract available
    
    
25. BELTRAN A, Parker L, Moral Pelaez I, Caballero-Romeu JP, et al
    Correction: Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice.
    PLoS One. 2025;20:e0339626.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

26. ZHANG Y, Ren H, Ma C, Shi C, et al
    A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity.
    Proc Natl Acad Sci U S A. 2025;122:e2505658122.
    PubMed         Abstract available
    
    
27. LIN Y, Wang R, Li F, Lu Z, et al
    Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2504904123.
    PubMed         Abstract available
    
    

    
    Prostate

28. ONO Y, Kohada Y, Tasaka S, Miyamoto S, et al
    Combining Prostate-Specific Antigen Density With PI-RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion-Targeted Re-Biopsy.
    Prostate. 2025 Dec 23. doi: 10.1002/pros.70117.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.